Literature DB >> 31599080

Prefrontal GABA and glutamate levels correlate with impulsivity and cognitive function of prescription opioid addicts: A 1 H-magnetic resonance spectroscopy study.

Jian-Neng Li1, Xi-Long Liu2, Long Li3.   

Abstract

AIM: Prescription opioids are psychoactive substances that can elicit many neuropsychological effects. There are no studies that directly demonstrate the effects of prescription opioid addiction (POA) on the human brain. This study aimed to quantify γ-aminobutyric acid (GABA) and glutamate (Glu) levels in the prefrontal cortex (PFC) of POA patients using proton magnetic resonance spectroscopy (1 H-MRS), and to explore their association with impulsive behavior and cognitive impairment.
METHODS: Thirty-five patients with a definitive clinical diagnosis of codeine-containing cough syrup dependence and 35 matched healthy controls underwent neuropsychological assessments, namely the Barratt Impulsiveness Scale (BIS-11) and the Montreal Cognitive Assessment Scale (MoCA). Point-resolved spectroscopy was performed to detect GABA and glutamate within the medial PFC, and the corresponding levels were estimated using jMRUI and corrected for fraction of cerebrospinal fluid in the 1 H-MRS voxel. The difference in metabolite levels between groups and the correlation between metabolite levels and psychometric scores in patients were analyzed statistically.
RESULTS: The peak level predominantly consisting of GABA with a relatively small influence of other chemicals (GABA+) was lower and that of glutamate was higher in the PFC of POA patients than in healthy controls. GABA+ levels correlated negatively with BIS-11 scores but correlated positively with MoCA scores. In contrast, glutamate levels showed a positive correlation with BIS-11 scores but no significant correlation with MoCA scores.
CONCLUSION: The quantitative in vivo measurement of GABA and glutamate levels in the PFC by 1 H-MRS could be a reliable way to evaluate impulsivity and cognitive function of POA.
© 2019 The Authors. Psychiatry and Clinical Neurosciences © 2019 Japanese Society of Psychiatry and Neurology.

Entities:  

Keywords:  glutamate; neuropsychology; prefrontal cortex; prescription opium dependence; γ-aminobutyric acid

Year:  2019        PMID: 31599080     DOI: 10.1111/pcn.12940

Source DB:  PubMed          Journal:  Psychiatry Clin Neurosci        ISSN: 1323-1316            Impact factor:   5.188


  6 in total

Review 1.  The effects of early life stress on impulsivity.

Authors:  Evelyn Ordoñes Sanchez; Debra A Bangasser
Journal:  Neurosci Biobehav Rev       Date:  2022-03-24       Impact factor: 9.052

2.  Examination of gamma-aminobutyric acid and glutamate-glutamine levels in association with impulsive behavior in adolescent marijuana users.

Authors:  Punitha Subramaniam; Andrew Prescot; Erin McGlade; Perry Renshaw; Deborah Yurgelun-Todd
Journal:  Drug Alcohol Depend       Date:  2022-01-25       Impact factor: 4.852

Review 3.  Quantifying GABA in Addiction: A Review of Proton Magnetic Resonance Spectroscopy Studies.

Authors:  Claire Shyu; Sofia Chavez; Isabelle Boileau; Bernard Le Foll
Journal:  Brain Sci       Date:  2022-07-13

4.  Higher glutamatergic activity in the medial prefrontal cortex in chronic ketamine users.

Authors:  Qiuxia Wu; Jinsong Tang; Chang Qi; An Xie; Jianbin Liu; Joseph O'Neill; Tieqiao Liu; Wei Hao; Yanhui Liao
Journal:  J Psychiatry Neurosci       Date:  2022-07-26       Impact factor: 5.699

Review 5.  Allosteric Modulators of Metabotropic Glutamate Receptors as Novel Therapeutics for Neuropsychiatric Disease.

Authors:  Deborah J Luessen; P Jeffrey Conn
Journal:  Pharmacol Rev       Date:  2022-07       Impact factor: 18.923

6.  GABA and glutamate deficits from frontotemporal lobar degeneration are associated with disinhibition.

Authors:  Alexander G Murley; Matthew A Rouse; P Simon Jones; Rong Ye; Frank H Hezemans; Claire O'Callaghan; Polytimi Frangou; Zoe Kourtzi; Catarina Rua; T Adrian Carpenter; Christopher T Rodgers; James B Rowe
Journal:  Brain       Date:  2020-12-05       Impact factor: 13.501

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.